Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.5999
Open
0.5944
VWAP
0.58
Vol
452.42K
Mkt Cap
9.82M
Low
0.5562
Amount
261.11K
EV/EBITDA(TTM)
--
Total Shares
8.62M
EV
5.92M
EV/OCF(TTM)
--
P/S(TTM)
14.34
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.340
-53.92%
--
--
-0.200
-56.52%
--
--
-0.200
-58.33%
Estimates Revision
The market is revising No Change the revenue expectations for iBio, Inc. (IBIO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -24.78%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-24.78%
In Past 3 Month
1 Analyst Rating
741.47% Upside
Wall Street analysts forecast IBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBIO is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
741.47% Upside
Current: 0.594
Low
5.00
Averages
5.00
High
5.00
741.47% Upside
Current: 0.594
Low
5.00
Averages
5.00
High
5.00
LUCID CAPITAL MARKETS
Dev Prasad
Strong Buy
Initiates
$6
2024-12-17
Reason
LUCID CAPITAL MARKETS
Dev Prasad
Price Target
$6
2024-12-17
Initiates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for iBio Inc (IBIO.A) is -0.63, compared to its 5-year average forward P/E of -4.67. For a more detailed relative valuation and DCF analysis to assess iBio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.67
Current PE
-0.63
Overvalued PE
2.90
Undervalued PE
-12.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
83.43
Current PS
144.54
Overvalued PS
178.94
Undervalued PS
-12.07
Financials
Annual
Quarterly
FY2025Q3
0.00
Total Revenue
FY2025Q3
YoY :
+34.56%
-4.88M
Operating Profit
FY2025Q3
YoY :
+84.48%
-4.86M
Net Income after Tax
FY2025Q3
YoY :
-42.35%
-0.49
EPS - Diluted
FY2025Q3
YoY :
-14.64%
-3.12M
Free Cash Flow
FY2025Q3
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q3
YoY :
-89.04%
-4.20K
FCF Margin - %
FY2025Q3
YoY :
-72.92%
-6.61K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
7
655.0K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
7
655.0K
USD
Months
0-12
0
0.0
USD
Months
IBIO News & Events
Events Timeline
2025-06-24 (ET)
2025-06-24
07:07:41
iBio, AstralBio unveil obesity program with amylin receptor agonist antibody
2025-06-16 (ET)
2025-06-16
07:06:23
iBio initiates non-human primate study of IBIO-610
2025-05-05 (ET)
2025-05-05
08:19:19
iBio announces new preclinical data for Activin E antibody
Sign Up For More Events
Sign Up For More Events
News
4.0
06-25BenzingaChardan Capital Maintains Buy on iBio, Maintains $5 Price Target
9.0
06-24NewsfilteriBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
9.0
06-24BenzingaWhy Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
MRKR
Marker Therapeutics Inc
1.190
USD
-3.25%
CPSH
CPS Technologies Corp
2.850
USD
+2.89%
DRRX
DURECT Corp
1.870
USD
-0.53%
PZG
Paramount Gold Nevada Corp
0.680
USD
+1.49%
HYFM
Hydrofarm Holdings Group Inc
4.490
USD
-1.32%
IGC
IGC Pharma Inc
0.340
USD
+0.29%
IPW
iPower Inc
0.590
USD
-3.28%
NXGL
Nexgel Inc
2.690
USD
+1.89%
CREX
Creative Realities Inc
2.390
USD
+2.58%
CTRM
Castor Maritime Inc
2.120
USD
0.00%
FAQ
What is iBio Inc (IBIO) stock price today?
The current price of IBIO is 0.5942 USD — it has increased 0 % in the last trading day.
What is iBio Inc (IBIO)'s business?
What is the price predicton of IBIO Stock?
What is iBio Inc (IBIO)'s revenue for the last quarter?
What is iBio Inc (IBIO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for iBio Inc (IBIO)'s fundamentals?
How many employees does iBio Inc (IBIO). have?